Results 51 to 60 of about 5,796 (217)
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 11, Page 1835-1847, November 2025.ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel +18 more
wiley +1 more source
Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3
Reviews in Medical Virology, Volume 35, Issue 6, November 2025.ABSTRACT Human parainfluenza virus‐type 3 (HPIV3) is a respiratory virus responsible for mild illnesses in most of the population and severe illnesses, such as bronchiolitis and pneumonia, in young children, immunocompromised individuals and the elderly.
Clémence Vacher +4 more
wiley +1 more source
Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro
The Turkish Journal of PediatricsBackground. Respiratory syncytial virus (RSV) is one of the most common pathogens causing severe lower respiratory tract disease in infancy and childhood.
Envera Lekic +5 more
doaj +1 more source
Pediatric Pulmonology, Volume 60, Issue 10, October 2025.ABSTRACT Background Bronchopulmonary dysplasia (BPD), a chronic lung disease in preterm infants, often leads to acute respiratory exacerbations triggered by infections. Our previous mouse study suggested that azithromycin's anti‐inflammatory properties may benefit virus‐induced respiratory illnesses prophylactically.
Ricardo A. Mosquera +17 more
wiley +1 more source
Influenza and Other Respiratory Viruses, Volume 19, Issue 10, October 2025.ABSTRACT Background Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection (ARI) in young children, but its genetic diversity requires ongoing surveillance. Methods From 2021 to 2023, a total of 619 and 94 RSV‐positive samples from the National Respiratory Syncytial Virus Surveillance Network (VigiRSV) and the Sentinel ...
Miguel Lança +8 more
wiley +1 more source
The clinical significance of palivi-zumab in the prevention of severe respiratory infections in newborn infants [PDF]
Саратовский научно-медицинский журнал, 2016 Palivizumab is known as the world's first drug with proven efficacy for passive immunization of severe infections of lower respiratory tract in preterm infants.
Bykova Е.М. +5 more
doaj
BMC Research Notes, 2012 Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and those with cardiopulmonary ...
Turti Tatyana V +10 more
doaj +1 more source
Influenza and Other Respiratory Viruses, Volume 19, Issue 10, October 2025.ABSTRACT Background Nirsevimab, a long‐acting monoclonal antibody, was shown to prevent respiratory syncytial virus (RSV) infections in newborns. We evaluated the cost‐effectiveness of nirsevimab strategies for newborns from the societal perspective in Hong Kong. Methods A Markov model was developed to simulate outcomes of four nirsevimab strategies in
Yingcheng Wang +4 more
wiley +1 more source
Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina
Journal of Pediatric and Neonatal Individualized Medicine, 2016 Background: Palivizumab is indicated for respiratory syncytial virus (RSV) prophylaxis in high-risk children. Methods: Observational study, based on 4 sites in Bosnia and Herzegovina (B&H), with institutional reports of infants at high risk for RSV ...
Suada Heljic +8 more
doaj +1 more source
1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY) [PDF]
, 2023 Deidre Wilkins +8 more
openalex +1 more source